Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "hormone" wg kryterium: Temat


Wyświetlanie 1-4 z 4
Tytuł:
The use of fulvestrant in patients with advanced breast cancer
Autorzy:
Kufel-Grabowska, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1035843.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
breast cancer
fulvestrant
hormone therapy
Opis:
Breast cancer is the most common malignancy in women in Poland and the entire world, but thanks to early diagnostics and efficacious therapeutic methods, its prognosis is good. In some patients with advanced breast cancer, long-term survival is observed, which is why it is essential to select the most appropriate therapy, and to follow up on the course of disease and possible adverse events related to the treatment applied. The slow development of hormone-receptor-positive cancer, and a multitude of therapeutic options constitute a real challenge in palliative treatment. The use of fulvestrant resulted in a good response in both of the presented cases, and did not in any way comprise the daily lives of the patients over a long period of time.
Źródło:
OncoReview; 2018, 8, 1; 15-18
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prostate cancer in an elderly patient with a history of comorbidities
Autorzy:
Stryczyńska-Mirocha, Adriana
Mirocha, Martyna
Powiązania:
https://bibliotekanauki.pl/articles/22676694.pdf
Data publikacji:
2023-03-31
Wydawca:
Medical Education
Tematy:
prostate cancer
hormone therapy
nmCRPC
apalutamide
Opis:
Prostate cancer is the most common cancer in men in Poland. The choice of treatment method depends on many factors, including the stage of the disease, the patient's age, life expectancy, the presence of comorbidities and the general condition of the patient. Hormone therapy is one of the basic methods of prostate cancer treatment, both in adjuvant and palliative treatment. Castration-resistant prostate cancer is an incurable disease. However, the introduction of new hormonal drugs to therapy significantly extended the survival time of patients with relatively low harmfulness of therapy.
Źródło:
OncoReview; 2023, 13, 1; 3-5
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Abiraterone acetate - 10 clinically relevant facts
Autorzy:
Żołnierek, Jakub
Powiązania:
https://bibliotekanauki.pl/articles/2047213.pdf
Data publikacji:
2021-09-30
Wydawca:
Medical Education
Tematy:
prostate cancer
systemic therapy
hormone therapy
abiraterone acetate
Opis:
Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
Źródło:
OncoReview; 2021, 11, 3; 80-84
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Autorzy:
Witek, Przemysław
Gutowska, Marta
Powiązania:
https://bibliotekanauki.pl/articles/1064786.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
acromegaly
growth hormone
insulin-like growth factor 1
lanreotide
long-acting somatostatin analogues
octreotide
pasireotide
somatotroph pituitary adenoma
tumour volume reduction
Opis:
Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth factor 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adenoma. The main goal of treatment is to normalise both GH and IGF-1 levels, which reduces symptoms, complications and mortality. Transsphenoidal selective adenomectomy performed by an experienced neurosurgeon is the first-line therapy. Therapy with somatostatin analogues (SSA) is used as a neoadjuvant treatment prior to surgery and in a persistent disease following the surgery. The long-acting somatostatin analogues reduce serum GH/IGF-1 levels and tumour volume. In this clinical review, mechanisms and role of 1st and 2nd generation somatostatin analogues in the treatment of patients with acromegaly are presented, with particular emphasis on the effects on somatotroph pituitary adenoma volume reduction.
Źródło:
OncoReview; 2016, 6, 4; A162-168
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-4 z 4

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies